AU7602400A - Secreted proteins and uses thereof - Google Patents

Secreted proteins and uses thereof

Info

Publication number
AU7602400A
AU7602400A AU76024/00A AU7602400A AU7602400A AU 7602400 A AU7602400 A AU 7602400A AU 76024/00 A AU76024/00 A AU 76024/00A AU 7602400 A AU7602400 A AU 7602400A AU 7602400 A AU7602400 A AU 7602400A
Authority
AU
Australia
Prior art keywords
uses
secreted proteins
secreted
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76024/00A
Inventor
Thomas Barnes
Christopher C Fraser
Gillian Kingsbury
Susan J. Kirst
John D. Sharp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US39972399A priority Critical
Priority to US09399723 priority
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to PCT/US2000/025982 priority patent/WO2001021631A2/en
Publication of AU7602400A publication Critical patent/AU7602400A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
AU76024/00A 1999-09-20 2000-09-20 Secreted proteins and uses thereof Abandoned AU7602400A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US39972399A true 1999-09-20 1999-09-20
US09399723 1999-09-20
PCT/US2000/025982 WO2001021631A2 (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU7602400A true AU7602400A (en) 2001-04-24

Family

ID=23580710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76024/00A Abandoned AU7602400A (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof

Country Status (3)

Country Link
EP (1) EP1218411A4 (en)
AU (1) AU7602400A (en)
WO (1) WO2001021631A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389722A1 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, a novel immunoregulatory molecule
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
PT1436003E (en) * 2001-05-24 2010-03-12 Zymogenetics Inc Taci-immunoglobulin fusion proteins
US8652465B2 (en) 2005-06-08 2014-02-18 Emory University Methods and compositions for the treatment of persistent infections
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
EP2370593B1 (en) 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
JP6091752B2 (en) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Treatment of native erythropoietin by suppressing the antisense transcript (epo) related diseases for Epo
EP2370581B1 (en) 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
TW201712034A (en) 2008-12-09 2017-04-01 Genentech Inc Anti-PD-L1 antibodies and their use to enhance t-cell function
WO2010093906A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
US9074210B2 (en) 2009-02-12 2015-07-07 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
CA2755409A1 (en) 2009-03-16 2010-09-23 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CN102549159B (en) 2009-03-17 2016-08-10 库尔纳公司 By suppressing natural antisense transcript for the δ-like 1 homolog (DLK1) treating a disease associated DLK1
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment related tristetraprolina (TTP) diseases by inhibiting natural antisense transcript for TTP
JP5883782B2 (en) 2009-05-06 2016-03-15 クルナ・インコーポレーテッド Treatment of lipid transport metabolic gene associated disease by suppressing the natural antisense transcript on lipid transport metabolism genes
ES2618572T3 (en) 2009-05-08 2017-06-21 Curna, Inc. Treatment related to the family of dystrophin diseases by inhibiting a natural antisense transcript for the family of dmd
CA2762369A1 (en) 2009-05-18 2010-11-25 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (en) 2009-05-22 2017-09-26 库尔纳公司 By inhibiting transcription factor for e3 (tfe3) natural antisense transcript treating TFE3 protein and insulin receptor substrate 2 (irs2) related diseases
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
ES2629339T3 (en) 2009-06-16 2017-08-08 Curna, Inc. Treatment related Paraoxonase1 (PON1) diseases by inhibiting natural antisense transcript to PON1
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing natural antisense transcript Down's syndrome gene therapy Down's syndrome gene-related diseases
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN102625841A (en) 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment related transcription factor peptidase membrane, site 1 (mbtps1) by inhibiting the natural antisense transcript to mbtps1 gene diseases
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc Treatment of hepatocytvækstfaktor- (HGF) related diseases by inhibition of the natural antisense transcript against HGF
CN102782134B (en) 2009-12-29 2017-11-24 库尔纳公司 By inhibiting NRF 1 (nrf1) natural antisense transcripts treating related diseases NRF1
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 63 is by inhibiting tumor protein (p63) of a natural antisense transcript treating p63 associated diseases
CN102791862B (en) 2009-12-31 2017-04-05 库尔纳公司 By inhibiting insulin receptor substrate 2 (irs2) and transcription factor e3 (tfe3) natural antisense transcripts treating related diseases IRS2
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc Treatment of interferon regulatory factor 8- (irf8) related diseases by inhibition of the natural antisense transcript against irf8
RU2612161C2 (en) 2010-01-06 2017-03-02 Курна, Инк. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
CA2786535A1 (en) 2010-01-11 2011-07-14 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
EP2553098B1 (en) 2010-04-02 2017-10-11 CuRNA, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CN107988228A (en) 2010-05-03 2018-05-04 库尔纳公司 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to sirtuin (sirt)
TWI531370B (en) 2010-05-14 2016-05-01 Curna Inc Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
KR101857090B1 (en) 2010-05-26 2018-06-26 큐알엔에이, 인크. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
JP6023705B2 (en) 2010-06-23 2016-11-09 カッパーアールエヌエー,インコーポレイテッド Treatment of sodium channel, voltage-dependent, SCNA related diseases by inhibition of the natural antisense transcripts for α-subunit (SCNA)
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
RU2624048C2 (en) 2010-10-06 2017-06-30 Курна, Инк. Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition
CN103180445B (en) 2010-10-22 2018-02-16 库尔纳公司 By inhibiting α-L- iduronic acid enzyme (IDUA) natural antisense transcripts treating related diseases IDUA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
CA2838588A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2825648B1 (en) 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
CA2320618A1 (en) * 1998-02-11 1999-08-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1056764A4 (en) * 1998-02-18 2001-08-29 Genetics Inst Secreted proteins and polynucleotides encoding them
EP1130094A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
WO2001021631A3 (en) 2001-11-22
EP1218411A4 (en) 2004-09-01
WO2001021631A2 (en) 2001-03-29
EP1218411A2 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
EP1194164B8 (en) Prion protein peptides and uses thereof
AU3441400A (en) Peptide
AU2002320013A1 (en) Human secreted proteins
AU2055401A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7573000A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3774300A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883700A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2434199A (en) Protein
AU6030398A (en) Human proteins
AU2883900A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2002368010A1 (en) Novel nucleic acids and secreted polypeptides
AU1220001A (en) Novel proteins and polynucleotides encoding them
EP1212343A4 (en) 52 human secreted proteins
EP1218408A4 (en) 32 human secreted proteins
AU4682999A (en) 94 human secreted proteins
AU5134799A (en) 98 human secreted proteins
AU6820000A (en) Novel proteases and variants thereof
AU6063500A (en) Glycoprotein vi and uses thereof
AU6241698A (en) Tace-like and matrilysin-like polypeptides
AU2002246502A1 (en) Nucleic acids and polypeptides
AU8047101A (en) Novel secreted proteins and their uses
AU2306499A (en) 110 human secreted proteins
AU3899700A (en) Secreted proteins and polynucleotides encoding them
AU2002309514A1 (en) Replikin peptides and uses thereof
EP1224285A4 (en) 27 human secreted proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase